Neoantigens encoded in the cancer genome

Current Opinion in Immunology

Volumn 41, Issue , 2016, Pages 98-103

  Schumacher, Ton N ^a   Hacohen, Nir ^b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN; HLA ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEOANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

ANTIGEN FUNCTION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; DNA DAMAGE; GENE MUTATION; GENETIC CODE; GENETIC HETEROGENEITY; HUMAN; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MOLECULAR CLONING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; RNA SPLICING; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR GENE; TUMOR IMMUNITY; ANIMAL; GENETICS; GENOME; IMMUNOLOGY; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; GENOME; HUMANS; NEOPLASMS;

EID: 84984851145     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.07.005     Document Type: Review

References (44)

1. 1 Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
2. 2 Blank, C.U., Haanen, J.B., Ribas, A., Schumacher, T.N., CANCER IMMUNOLOGY. The cancer immunogram. Science 352 (2016), 658–660.
3. 3 Cobbold, M., De La Pena, H., Norris, A., Polefrone, J.M., Qian, J., English, A.M., Cummings, K.L., Penny, S., Turner, J.E., Cottine, J., et al. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med, 5, 2013, 203ra125.
4. 4 Giannakis, M., Mu, X.J., Shukla, S.A., Qian, Z.R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep, 2016.
5. 5 Howitt, B.E., Shukla, S.A., Konstantinopoulos, P.A., Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol 1 (2015), 1319–1323.
6. 6 Strickland, K.C., Howitt, B.E., Shukla, S.A., Rodig, S., Ritterhouse, L.L., Liu, J.F., Garber, J.E., Chowdhury, D., Wu, C.J., D'Andrea, A.D., et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7 (2016), 13587–13598.
7. 7 Matsushita, H., Sato, Y., Karasaki, T., Nakagawa, T., Kume, H., Ogawa, S., Homma, Y., Kakimi, K., Neoantigen load, antigen presentation machinery, and immune signatures determine prognosis in clear cell renal cell carcinoma. Cancer Immunol Res 4 (2016), 463–471.
8. 8 Brown, S.D., Warren, R.L., Gibb, E.A., Martin, S.D., Spinelli, J.J., Nelson, B.H., Holt, R.A., Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24 (2014), 743–750.
9. 9 Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
10. 10 Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
11. 11 Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (2014), 2189–2199.
12. 12 Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
13. 13 Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M.H., Goldinger, S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
14. 14 Schumacher, T.N., Kesmir, C., van Buuren, M.M., Biomarkers in cancer immunotherapy. Cancer Cell 27 (2015), 12–14.
15. 15 Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
16. 16 Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., Dawson, N., O'Donnell, P.H., Balmanoukian, A., Loriot, Y., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
17. 17 Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
18. 18 McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
19. 19 Peng, W., Chen, J.Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M.T., Xu, C., McKenzie, J.A., Zhang, C., Liang, X., et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6 (2016), 202–216.
20. 20 Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
21. 21 Mittal, D., Gubin, M.M., Schreiber, R.D., Smyth, M.J., New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol 27 (2014), 16–25.
22. 22•• Verdegaal, E.M., de Miranda, N.F., Visser, M., Harryvan, T., van Buuren, M.M., Andersen, R.A., Hadrup, S.R., van der Minne, C.E., Schotte, R., Spits, H., et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536 (2016), 91–95 Demonstration of the dynamic changes in the T cell-recognized neoantigen landscape in human cancer.
23. 23 Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., Lin, J.C., Teer, J.K., Cliften, P., Tycksen, E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19 (2013), 747–752.
24. 24 van Rooij, N., van Buuren, M.M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L.J., Behjati, S., Hilkmann, H., El Atmioui, D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31 (2013), e439–e442.
25. 25 Tran, E., Ahmadzadeh, M., Lu, Y.C., Gros, A., Turcotte, S., Robbins, P.F., Gartner, J.J., Zheng, Z., Li, Y.F., Ray, S., et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350 (2015), 1387–1390.
26. 26• Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Lower, M., Diekmann, J., Boegel, S., Schrors, B., Vascotto, F., Castle, J.C., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520 (2015), 692–696 Demonstration of the biased induction of neoantigen specific CD4+ T cell responses and the anti-tumor potential of neoantigen-specific CD4+ T cell responses.
27. 27 Ossendorp, F., Mengede, E., Camps, M., Filius, R., Melief, C.J., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187 (1998), 693–702.
28. 28•• Tran, E., Turcotte, S., Gros, A., Robbins, P.F., Lu, Y.C., Dudley, M.E., Wunderlich, J.R., Somerville, R.P., Hogan, K., Hinrichs, C.S., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344 (2014), 641–645 Demonstration that infusion of neoantigen-specific CD4 T cells can induce tumor control in a patient with metastatic cancer.
29. 29• Stronen, E., Toebes, M., Kelderman, S., van Buuren, M.M., Yang, W., van Rooij, N., Donia, M., Boschen, M.L., Lund-Johansen, F., Olweus, J., et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science, 2016 Development of technology to exploit the healthy donor T cell repertoire to obtain neoantigen-specific TCRs.
30. 30 Castle, J.C., Kreiter, S., Diekmann, J., Lower, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 72 (2012), 1081–1091.
31. 31 Kreiter, S., Castle, J.C., Tureci, O., Sahin, U., Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology 1 (2012), 768–769.
32. 32 Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C.D., Krebber, W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
33. 33 Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T.K., Fritsche, J., Weinschenk, T., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515 (2014), 572–576.
34. 34•• Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., Ly, A., Lie, W.R., Hildebrand, W.H., Mardis, E.R., et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 (2015), 803–808 First clinical trial in humans with peptide-pulsed DCs showing induction of neoantigen-specific T cell responses.
35. 35 Martin, S.D., Brown, S.D., Wick, D.A., Nielsen, J.S., Kroeger, D.R., Twumasi-Boateng, K., Holt, R.A., Nelson, B.H., Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS One, 11, 2016, e0155189.
36. 36 Kranz, L.M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K.C., Meng, M., Fritz, D., Vascotto, F., Hefesna, H., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016.
37. 37 Linnemann, C., van Buuren, M.M., Bies, L., Verdegaal, E.M., Schotte, R., Calis, J.J., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D.E., et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 21 (2015), 81–85.
38. 38 Cohen, C.J., Gartner, J.J., Horovitz-Fried, M., Shamalov, K., Trebska-McGowan, K., Bliskovsky, V.V., Parkhurst, M.R., Ankri, C., Prickett, T.D., Crystal, J.S., et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125 (2015), 3981–3991.
39. 39• Gros, A., Parkhurst, M.R., Tran, E., Pasetto, A., Robbins, P.F., Ilyas, S., Prickett, T.D., Gartner, J.J., Crystal, J.S., Roberts, I.M., et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22 (2016), 433–438 Development of a blood-based strategy to identify neoantigen and self antigen reactive T cells that may be used for therapy.
40. 40 Lundegaard, C., Lund, O., Nielsen, M., Prediction of epitopes using neural network based methods. J Immunol Methods 374 (2011), 26–34.
41. 41 Calis, J.J., Maybeno, M., Greenbaum, J.A., Weiskopf, D., De Silva, A.D., Sette, A., Kesmir, C., Peters, B., Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol, 9, 2013, e1003266.
42. 42 Birnbaum, M.E., Mendoza, J.L., Sethi, D.K., Dong, S., Glanville, J., Dobbins, J., Ozkan, E., Davis, M.M., Wucherpfennig, K.W., Garcia, K.C., Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157 (2014), 1073–1087.
43. 43 Chowell, D., Krishna, S., Becker, P.D., Cocita, C., Shu, J., Tan, X., Greenberg, P.D., Klavinskis, L.S., Blattman, J.N., Anderson, K.S., TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc Natl Acad Sci U S A 112 (2015), E1754–E1762.
44. 44 Tureci, O., Vormehr, M., Diken, M., Kreiter, S., Huber, C., Sahin, U., Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer Res 22 (2016), 1885–1896.